Western European markets for biosimilar and generic drugs: worth differentiating

European Journal of Health Economics

Volumn 16, Issue 7, 2015, Pages 683-687

  Garattini, Livio ^a   Curto, Alessandro ^a   van de Vooren, Katelijne ^a  

^a CESAV   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BIOSIMILAR AGENT; GENERIC DRUG;

DRUG COST; DRUG MARKETING; EDITORIAL; HEALTH PROMOTION; HUMAN; POLICY; PRIORITY JOURNAL; WESTERN EUROPEAN; DRUG APPROVAL; DRUG INDUSTRY; ECONOMICS; EUROPE; HEALTH CARE POLICY; SUPPLY AND DISTRIBUTION;

BIOSIMILAR PHARMACEUTICALS; DRUG APPROVAL; DRUG INDUSTRY; DRUGS, GENERIC; EUROPE; HEALTH POLICY; HUMANS;

EID: 84938995625     PISSN: 16187598     EISSN: 16187601     Source Type: Journal    
DOI: 10.1007/s10198-015-0684-y     Document Type: Editorial

References (34)

1. EMA. European Public Assessment Reports. Biosimilars. http://www.ema.europa.eu/ema/index.jsp?curl=pages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=WC0b01ac058001d124&searchTab=searchByAuthType&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keyword=Enter+keywords&searchType=name&taxonomyPath=&treeNumber=&searchGenericType=biosimilars&genericsKeywordSearch=Submit. Accessed 15 Jan 2015
2. McCarthy, J.E.: Basic marketing. A managerial approach. Irwin RD, Homewood (1964)
3. EMA/393905/2006 Rev 2. Questions and answers on generic medicines. http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2009/11/WC500012382.pdf (2012). Accessed 9 Dec 2014
4. EMA. CPMP/EWP/QWP/1401/98 Rev. 1/Corr **. Guideline on the investigation of bioequivalence. London. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500070039.pdf (2010). Accessed 9 Dec 2014
5. EMA/837805/2011. Questions and answers on biosimilar medicines (similar biological medicinal products). http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2009/12/WC500020062.pdf (2012). Accessed 9 Dec 2014
6. Dörner, T., Strand, V., Castañeda-Hernández, G., et al.: The role of biosimilars in the treatment of rheumatic diseases. Ann. Rheum. Dis. 72(3), 322–328 (2013)
7. Weise, M., Kurki, P., Wolff-Holz, E., Bielsky, M.C., Schneider, C.K.: Biosimilars: the science of extrapolation. Blood 124(22), 3191–3196 (2014)
8. van der Zee, J., Kroneman, M.W.: Bismarck or Beveridge: a beauty contest between dinosaurs. BMC Health Serv Res 7, 94 (2007)
9. Schäfer, W., Kroneman, M., Boerma, W., et al.: The Netherlands: health system review. Health Syst. Transit. 12(1), v–xxvii, 1–228 (2010)
10. Hassali, M.A., Wong, Z.Y., Alrasheedy, A.A., Saleem, F., Mohamad Yahaya, A.H., Aljadhey, H.: Perspectives of physicians practicing in low and middle income countries towards generic medicines: a narrative review. Health Policy 117(3), 297–310 (2014)
11. Garattini, L., Tediosi, F.: A comparative analysis of generics markets in five European countries. Health Policy 51(3), 149–162 (2000)
12. Miguel, L.S., Augustin, U., Busse, R., et al.: Recognition of pharmaceutical prescriptions across the European Union: a comparison of five Member States’ policies and practices. Health Policy 116(2–3), 206–213 (2014)
13. Taylor L. France moving ahead with biosimilar substitution. http://www.pharmatimes.com/Article/14-04-13/France_moving_ahead_with_biosimilar_substitution.aspx (2014). Accessed 9 Dec 2014
14. GKV-Spitzenverband. Rahmenvorgaben nach § 84 Abs. 7 SGB V—Arzneimittel—für das Jahr 2015 vom 26 September 2014. http://www.gkv-spitzenverband.de/suche/suche?default=true&query=biosimilar&x=0&y=0. Accessed 9 Dec 2014
15. Weise, M., Bielsky, M.C., De Smet, K., et al.: Biosimilars: what clinicians should know. Blood 120(26), 5111–5117 (2012)
16. Farfan-Portet, M.I., Gerkens, S., Lepage-Nefkens, I., et al.: Are biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures? Eur J Health Econ 15, 223–228 (2014)
17. Godman, B., Shrank, W., Wettermark, B., et al.: Use of generics—a critical cost containment measure for all healthcare professionals in Europe? Pharmaceuticals 3(8), 2470–2494 (2010)
18. Dylst, P., Vulto, A., Simoens, S.: Tendering for outpatient prescription pharmaceuticals: what can be learned from current practices in Europe? Health Policy 101(2), 146–152 (2011)
19. European Commission. Pharmaceuticals: sector inquiry and follow up. Final report, factsheet 1: prices, time to generic entry and consumer savings. http://ec.europa.eu/competition/sectors/pharmaceuticals/inquiry/index.html (2009). Accessed 9 Dec 2014
20. Woerkom, M.V., Piepenbrink, H., Godman, B., et al.: Ongoing measures to enhance the efficiency of prescribing of proton pump inhibitors and statins in the Netherlands: influence and future implications. J. Comp. Eff. Res. 1(6), 527–538 (2012)
21. Giuliani, G., Selke, G., Garattini, L.: The German experience in reference pricing. Health Policy 44(1), 73–85 (1998)
22. Bennett, C.L., Chen, B., Hermanson, T., et al.: Regulatory and clinical considerations for biosimilar oncology drugs. Lancet Oncol 15(13), e594–e605 (2014)
23. Blackstone, E.A., Joseph, P.F.: The economics of biosimilars. Am Health Drug Benefits 6(8), 469–478 (2013)
24. Curto, A., van de Vooren, K., Lo Muto, R., Duranti, S., Garattini, L.: Regional tenders on biosimilars in Italy, potentially competitive? GaBI J 2(3), 123–129 (2013)
25. Sahuquillo MR. El Gobierno lanza la primera compra centralizada de fármacos. El Pais 27 December 2011. http://sociedad.elpais.com/sociedad/2012/12/27/actualidad/1356641122_491730.html. Accessed 9 Dec 2014
26. Ortega E. Medicamentos biológicos de marca y biosimilares competirán en los mismos concursos públicos. Redacción Médica 25 November 2014. http://www.redaccionmedica.com/secciones/industria/biologicos-de-marca-y-biosimilares-competiran-en-los-mismos-concursos-publicos-5934. Accessed 9 Dec 2014
27. GaBI Journal. US$67 billion worth of biosimilar patents expiring before 2020. http://www.gabionline.net/Biosimilars/General/US-67-billion-worth-of-biosimilar-patents-expiring-before-2020 (2014). Accessed 9 Dec 2014
28. EMA CHMP/437/04. Guideline on similar biological medicinal products. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003517.pdf (2005). Accessed 9 Dec 2014
29. van de Vooren, K., Curto, A., Garattini, L.: Cost-effectiveness of trastuzumab in metastatic breast cancer: mainly a matter of price in the EU? Health Policy 119(2), 212–216 (2015)
30. PR Newswire. Celltrion signs manufacturing agreement with Bristol-Myers Squibb Company. http://www.prnewswire.co.uk/news-releases/celltrion-signs-manufacturing-agreement-with-bristol-myers-squibb-company-153811165.html (2014). Accessed 9 Dec 2014
31. Reuters. S.Korea’s Celltrion shares jump on reports of bid interests from Roche, Teva. http://www.reuters.com/article/2014/01/08/celltrion-sale-idUSL3N0KI0MD20140108 (2014). Accessed 9 Dec 2014
32. Brinks, V., Hawe, A., Basmeleh, A.H., et al.: Quality of original and biosimilar epoetin products. Pharm. Res. 28(2), 386–393 (2011)
33. DiMasi, J.A., Hansen, R.W., Grabowski, H.G.: The price of innovation: new estimates of drug development costs. J Health Econ 22(2), 151–185 (2003)
34. Curto, S., Ghislandi, S., van de Vooren, K., Duranti, S., Garattini, L.: Regional tenders on biosimilars in Italy: an empirical analysis of awarded prices. Health Policy 116(2–3), 182–187 (2014)